Navigation Links
Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Date:3/11/2008

ytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (Pink Sheets: VXGN.PK), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected to create a drug development company with a robust pipeline of mono
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
8. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
9. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
10. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... - New Progression-Free Survival Data Support Picoplatin ... for Metastatic Castration-Resistant Prostate Cancer -- Results ... of Clinical Oncology,s 2009 Genitourinary Cancers Symposium ... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ...
... China, Feb. 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... focused on researching,developing, manufacturing and marketing biopharmaceutical products, ... the fourth quarter and,full year ended December 31, ... 11, 2009. , Following ...
... and Sunflower Oils drive better restaurant menu optionsINDIANAPOLIS, Feb. ... significant milestone in North America with the reduction of ... fats over the past three years. Since the market ... by Dow AgroSciences, have replaced more than 340 million ...
Cached Biology Technology:Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 2Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 3Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 4Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 53SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 3
(Date:4/22/2014)... presented Beaumont Health System with prestigious, competitive research ... athletic and nonathletic injuries. , The American ... grant to fund stem cell-based research that could ... ruptured knee anterior cruciate ligament, or ACL. According ... cruciate ligament injury is the over-stretching or tearing ...
(Date:4/22/2014)... a trip to Asia to coordinate with allies ... officials at the Office of Naval Research (ONR) ... (APTEP) as an example of strong and growing ... in the region. , The APTEP program, centered ... supports the development of alternative energy technologies. It ...
(Date:4/22/2014)... how communities can protect themselves from worsening storms. ... New England and the Midwest providing practical and ... goal is to help communities begin the steps ... of Syntectic International, Portland, OR. "It,s important because ... beyond feeling paralyzed from the lack of local ...
Breaking Biology News(10 mins):Beaumont awarded grants to study sports-related injury treatment, improve recovery 2Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3Minnesota projects offer hope and practical help to communities facing more extreme storms 2
... staff scientist at Carnegie,s Department of Embryology, has ... American Academy of Microbiology. Fellows are annually elected ... their records of scientific achievement and original contributions ... single-celled yeast Saccharomyces cerevisiae , Koshland has ...
... bomb plot was uncovered in London in August 2006, ... (S&T) looked to to find ways to not only ... to figure out what those liquids are. Now, S&T-sponsored ... possible solution. They have successfully tested a liquid ...
... CSC (NYSE: CSC ) announced today that ... Operations and Support Services Unrestricted contract by the Department ... indefinite-delivery/indefinite-quantity (IDIQ) contract covers a broad range of services, ... of BTF business and program units. The contract has ...
Cached Biology News:Carnegie's Doug Koshland elected Fellow of the American Academy of Microbiology 2Good liquid, bad liquid 2CSC Awarded Department of Defense Biometrics Contract 2
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
... is especially formulated for non-denaturing polyacrylamide and ... gel loading solution contains a bromophenol blue ... and facilitate sample loading. EDTA has been ... cations and SDS has been added to ...
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
... Description: 100 g ... 70 kDa YAP from Human/mouse/rat samples. ... Research Focus: ... -20C Shipping ...
Biology Products: